



UNIVERSITA' DEGLI STUDI DI CATANIA

Dipartimento: Dipartimento di Scienze del Farmaco e della Salute

N.	Struttura amministrativo - contabile
4	DSFS

Catania,

9	12	2025
---	----	------

Al Dirigente A.Fi

Prot. N...	
Alleg.	Richiesta - preventivo
N.rich.	342

a cura dei servizi istituzionali

Id.gest.	cod.contab.	ente
<	20016	40

a cura dei servizi contabili

Oggetto: nota istruttoria n. 342

Struttura richiedente	
Descrizione	
C.R.	Dipartimento di Scienze del Farmaco e della Salute
C.C.	
DOC.	Prof. F. Pappalardo
a cura	servizi istituzionali

Spesa finalizzata (1):	
	Forniture
	Utenze
X	Servizi (incluse manut. attrezzature)
	Missioni
	Contratti co.co.co e occasionali
	Contratti d'insegnamento
	Assegni di ricerca
	altro:

Inoltare le richieste per singola tipologia

La spesa viene imputata :		Finanziam.interno/esterno
Budget Dipartimento		
C/ Terzi		
Progetto:		
codice Progetto:		
CUP:		
Resp.Scientif.:		
X	Fondi di Ricerca	X

a cura dei servizi istituzionali

(1) Specificare in dettaglio la spesa da sostenere per singola tipologia						
interventi	DESCRIZIONE ANALITICA DELLA SPESA	IMPORTO	CODICE CAPITOLO	ES.	Impegno provvisorio	Co.An.
1	Pubblicazione Scientifica - Open Source Springer Nature n. invoice 2936755421	3.045,00				
	IVA 4% ISSN 2056-7189	121,80				
	Totale	3.166,80				

a cura dei servizi contabili

Ulteriori informazioni

Su indicazioni del Direttore del DSFS si nomina RUP: Rag. G. Maugeri

a cura dei servizi istituzionali

Il Direttore del Dipartimento

Il Responsabile Amministrativo Gestionale

Il Responsabile Funzionario Contabile

X	conosc.
XX	comp.

Direzione amm.va Aree	competenza conoscenza
Direzione amm.va	X
AFI	XX
ARIT	
ACUC	
ADI	
ARI	
ATM	
ACOM	
ARU	
ULA	
ASEG	

altre strutture di servizio	competenza conoscenza
Tipografia	

compilazione a cura dei servizi istituzionali
trasmissione a cura dei servizi contabili



UNIVERSITÀ
degli STUDI
di CATANIA

**DIPARTIMENTO DI SCIENZE
DEL FARMACO E DELLA SALUTE**

IL PROF. Francesco Pappalardo
FONDO "PHARMA-HUB T4-AN-04 prof.ssa A. Copani"

UPB: 57725172065
CUP: E63C22001680001

SI RICHIEDE

Prodotto	Q.tà da ordinare	IMPORTO unit.	IMPORTO tot.
Pubblicazione scientifica open-source: "Computational modeling of ATM signaling: a predictive framework for drug repurposing in ataxia-telangiectasia" Journal Name: npj Systems Biology and Applications DOI: 10.1038/s41540-025-00629-4 ISSN: 2056-7189	1	3.045,00	3.045,00
		<i>Totale Iva esclusa</i>	3.045,00
		<i>Iva 4%</i>	121,8
		<i>Totale Iva inclusa</i>	EUR 3.166,80

Catania, 27/11/2025

Il Richiedente

Francesco Pappalardo

Il Responsabile del Fondo

Agata Copani

All'Ufficio amministrativo e del personale
All'Ufficio provveditoriale

Prot. n.
Allegati:

RICHIESTA AFFIDAMENTO SERVIZIO O FORNITURA

OGGETTO	SERVIZIO	☒ FORNITURA
	Pubblicazioni open source	
MOTIVAZIONI CHE GIUSTIFICANO LA RICHIESTA	Pubblicazioni scientifiche su progetto	
MOTIVAZIONI CHE GIUSTIFICANO L'EVENTUALE URGENZA		
IMPORTO PRESUNTO (comprensivo di eventuali rinnovi)	<input checked="" type="checkbox"/> sino ad Euro 10.000,00	€, esclusa IVA
	<input type="checkbox"/> compreso tra Euro 10.000,00 ed Euro 40.000,00	€, esclusa IVA
	<input type="checkbox"/> superiore ad Euro 40.000,00	€, esclusa IVA
Clausole essenziali del servizio/fornitura richiesto		
DATI DI BILANCIO	IMPORTO PRESUNTO: EUR 3166,80	
	UPB: 57725172065	IMPEGNO: DESCRIZIONE "PHARMA-HUB T4-AN-04 prof.ssa A. Copani"
CUP (ove previsto)	E63C22001680001	

Catania, 27/11/2025

Il richiedente
Francesco Pappalardo

Francesco Pappalardo

Il titolare del fondo
Agata Copani

Agata Copani

INVOICE

Springer Nature Customer Service Center GmbH www.springernature.com
Europaplatz 3
69115 Heidelberg | Germany
VAT ID.DE209719094

SPRINGER NATURE

Our Reference No. > 2936755421 **Finance Account No.** > 2201501211 **Customer Account No.** > 3008098509 **Purchase Order No.** > **Customer VAT ID** > IT02772010878 **Date** 21.11.2025 **Pages** 1 / 2

Bill to

Ship to

> University of Catania
DSFS
V.le A. Doria 6
95125 CATANIA
Italy

Francesco Pappalardo
University of Catania
V.le A. Doria 6
95125 CATANIA
Italy

Quantity	Product No.	Description	List Price	Disc. %	VAT	Amount
1	43930E	Single APC Order: 0100375324 Open: Man Apc price Open: man.ReducePr. Open:APC+ Discount	2.990,00 2.990,00		A	2.990,00
		Manuscript ID: F3838A39-A58A-4501-8D8D-72EC6E50B90 DOI:10.1038/S41540-025-00629-4 Journal Name: npj Systems Biology and Applications Author Name: Francesco Pappalardo Manuscript Title:Computational modeling of ATM signaling: a predictive framework for drug repurposing in ataxia-telangiectasia Customer to self-assess VAT (reverse charge), Article 44 & 196 of EC Directive 2006/112				
1	80078E	Single APC Admin Fee Order: 0100375324 Open: Admin Fee Customer to self-assess VAT (reverse charge), Article 44 & 196 of EC Directive 2006/112	55,00		A	55,00

VAT Reverse Charge, the customer is liable for the VAT due

The European Union's (EU) General Product Safety Regulation (GPSR) is a set of rules that requires consumer products to be safe and our obligations to ensure this.

If you have any concerns about our products, you can contact us at: ProductSafety@springernature.com

In case Publisher is established outside the EU, the EU authorized representative is:
Springer Nature Customer Service Center GmbH
Europaplatz 3
69115 Heidelberg, Germany

Subtotal

3.045,00

INVOICE

Springer Nature Customer Service Center GmbH www.springernature.com
 Europaplatz 3
 69115 Heidelberg | Germany
 VAT ID.DE209719094

SPRINGER NATURE

Our Reference No. > 2936755421	Finance Account No. > 2201501211	Customer Account No. > 3008098509	Purchase Order No. >	Customer VAT ID > IT02772010878	Date 21.11.2025	Pages 2 / 2
--	--	---	--------------------------------	---	---------------------------	-----------------------

--	--	--	--	--	--	--

Net Value Goods C	0,00	Net Value Goods B	0,00	Net Value Goods A	3.045,00	Total Net Value of Goods	3.045,00
Net Shipping Costs C	0,00	Net Shipping Costs B	0,00	Net Shipping Costs A	0,00	Total Net Shipping Costs	0,00
Total Net C	0,00	Total Net B	0,00	Total Net A	3.045,00	Total Net Due	3.045,00
Incoterms DDP	VAT C	VAT B	VAT A	Total VAT			0,00
Subtotal							3.045,00
Prepaid							0,00
TOTAL DUE							EUR 3.045,00

For all your support needs and contact options, please visit support.springernature.com
 For Remittance Advice and proof of payment, please email them at ARadvice@springernature.com
 For overdue and pre collection letters: Collections.OpenAccess@springernature.com

Remit a payment in Euro to:
 Bank details: **Hypovereinsbank München**
 Account: 654793298 - Sort code : 70020270
 IBAN: DE22 7002 0270 0654 7932 98
 BIC: HYVEDEMMXXX

To pay by credit card:
 Scan QR-code or send an E-mail to: creditcard@springernature.com
 for a secure payment link
 Do not send us your credit card details



Payable net 30 days

Thank you for your order.



SPRINGER NATURE

Springer Nature Customer Service Center GmbH | Europaplatz 3 | 69115 Heidelberg | Germany
 Commercial Register: Amtsgericht Mannheim | HRB 336546
 Managing Directors: Alexandra Dambeck, Harald Wirsching

[nature](#) > [npj systems biology and applications](#) > [articles](#) > [article](#)[Download PDF](#)Article | [Open access](#) | Published: 24 November 2025

Computational modeling of ATM signaling: a predictive framework for drug repurposing in ataxia-telangiectasia

[Aurora Eliana Merulla](#), [Valentina Di Salvatore](#), [Giorgia Serena Gullotta](#), [Avisa Maleki](#), [Giulia Russo](#), [Filippo Caraci](#), [Agata Copani](#) & [Francesco Pappalardo](#) 

[npj Systems Biology and Applications](#), Article number: (2025)

119 Accesses | [Metrics](#)




We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply.

Abstract

Ataxia-Telangiectasia (A-T) is a rare genetic disorder caused by ATM mutations, leading to impaired DNA repair, oxidative stress, and neurodegeneration. We developed a computational model of ATM-mediated signaling using ordinary differential equations in COPASI, capturing key processes including DNA damage sensing, cell cycle regulation, autophagy, and oxidative stress response. The model simulates physiological, ATM-deficient, and drug-treated conditions to explore repurposing strategies. We evaluated the effects of spermidine, omaveloxolone,


and HDAC4 inhibition, revealing mechanisms by which these compounds modulate dysfunctional signaling. Sensitivity and stability analyses confirmed the model's robustness, while enrichment analysis validated involvement of key pathways. Our results highlight the synergistic potential of combining autophagy activation and epigenetic modulation to partially restore homeostasis in ATM-deficient cells. This work introduces a generalizable modeling framework for simulating disease-specific signaling dysfunction and identifying therapeutic interventions, illustrating the value of computational systems biology in rare disease drug repurposing.

Similar content being viewed by others




Cellular functions of the protein kinase ATM and their relevance to human disease

Article | 24 August 2021



Molecular basis of human ATM kinase inhibition

Article | 23 September 2021



Loss of CD98HC phosphorylation by ATM impairs antiporter trafficking and drives...

Article | Open access
02 June 2025

Data availability

The model is available in a GitHub repository, visiting the following URL:

<https://github.com/francescopappalardo/ATM-ATR-DDR-DrugRepositioning-Model>.

References

1. Rothblum-Oviatt, C. et al. Ataxia telangiectasia: a review. *Orphanet J. Rare Dis.* **11**, 159 (2016).
2. Amirifar, P., Ranjouri, M. R., Yazdani, R., Abolhassani, H. & Aghamohammadi, A. Ataxia-telangiectasia: a review of clinical features and molecular pathology. *Pediatr. Allergy Immunol.* **30**, 277–288 (2019).
3. van Os, N. J. H. et al. Classic ataxia-telangiectasia: the phenotype of long-term survivors. *J. Neurol.* **267**, 830–837 (2020).
4. Riboldi G. M. *Ataxia-Telangiectasia* (StatPearls Publishing, 2024).
5. Shiloh, Y. & Ziv, Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. *Nat. Rev. Mol. Cell Biol.* **14**, 197–210 (2013).
6. Mitiagin, Y. & Barzilai, A. Ataxia-telangiectasia mutated plays an important role in cerebellar integrity and functionality. *Neural Regen. Res.* **18**, 497–502 (2023).
7. Choy, K. R. & Watters, D. J. Neurodegeneration in ataxia-telangiectasia: multiple roles of ATM kinase in cellular homeostasis. *Dev. Dyn.* **247**, 33–46 (2018).

8. Watters, D. et al. Localization of a portion of extranuclear ATM to peroxisomes. *J. Biol. Chem.* **274**, 34277–34282 (1999).
9. Barlow, C. et al. ATM is a cytoplasmic protein in mouse brain required to prevent lysosomal accumulation. *Proc. Natl Acad. Sci. USA* **97**, 871–876 (2000).
10. Boehrs, J. K., He, J., Halaby, M. J. & Yang, D. Q. Constitutive expression and cytoplasmic compartmentalization of ATM protein in differentiated human neuron-like SH-SY5Y cells. *J. Neurochem.* **100**, 337–345 (2007).
11. Valentin-Vega, Y. A. et al. Mitochondrial dysfunction in ataxia-telangiectasia. *Blood* **119**, 1490–1500 (2012).
12. Guo, Z., Kozlov, S., Lavin, M. F., Person, M. D. & Paull, T. T. ATM activation by oxidative stress. *Science* **330**, 517–521 (2010).
13. Alexander, A. et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. *Proc. Natl Acad. Sci. USA* **107**, 4153–4158 (2010).
14. Stern, N. et al. Accumulation of DNA damage and reduced levels of nicotine adenine dinucleotide in the brains of *Atm*-deficient mice. *J. Biol. Chem.* **277**, 602–608 (2002).

15. Kamsler, A. et al. Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from Atm-deficient mice. *Cancer Res.* **61**, 1849–1854 (2001).
16. Cam, H., Easton, J. B., High, A. & Houghton, P. J. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1alpha. *Mol. Cell* **40**, 509–520 (2010).
17. Yang, Y. & Herrup, K. Loss of neuronal cell cycle control in ataxia-telangiectasia: a unified disease mechanism. *J. Neurosci.* **25**, 2522–2529 (2005).
18. Yang, Y., Hui, C. W., Li, J. & Herrup, K. The interaction of the atm genotype with inflammation and oxidative stress. *PLoS ONE* **9**, e85863 (2014).
19. Li, J. et al. Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia. *Nat. Med.* **18**, 783–790 (2012).
20. Campbell, A. et al. Mutation of ataxia-telangiectasia mutated is associated with dysfunctional glutathione homeostasis in cerebellar astroglia. *Glia* **64**, 227–239 (2016).
21. Raz-Prag, D. et al. A role for vascular deficiency in retinal pathology in a mouse model of ataxia-telangiectasia. *Am. J. Pathol.* **179**, 1533–1541 (2011).

22. Levi, H. et al. Dysfunction of cerebellar microglia in ataxia-telangiectasia. *Glia* **70**, 536–557 (2022).
23. Levchenko, A. Dynamical and integrative cell signaling: challenges for the new biology. *Biotechnol. Bioeng.* **84**, 773–782 (2003).
24. Warne, D. J., Baker, R. E. & Simpson, M. J. Simulation and inference algorithms for stochastic biochemical reaction networks: from basic concepts to state-of-the-art. *J. R. Soc. Interface* **16**, 20180943 (2019).
25. Kaitin, K. I. Deconstructing the drug development process: the new face of innovation. *Clin. Pharm. Ther.* **87**, 356–361 (2010).
26. Karaman, B. & Sippl, W. Computational drug repurposing: current trends. *Curr. Med. Chem.* **26**, 5389–5409 (2019).
27. Mendes, P. et al. Computational modeling of biochemical networks using COPASI. *Methods Mol. Biol.* **500**, 17–59 (2009).
28. Hoops, S. et al. COPASI—a COMplex PATHway Simulator. *Bioinformatics* **22**, 3067–3074 (2006).

29. Gianì, F. et al. Computational modeling reveals MAP3K8 as mediator of resistance to vemurafenib in thyroid cancer stem cells. *Bioinformatics* **35**, 2267–2275 (2019).

30. Tyson, J. J., Chen, K. C. & Novak, B. Sniffers, buzzers, toggles and blinkers: dynamics of regulatory and signaling pathways in the cell. *Curr. Opin. Cell Biol.* **15**, 221–231 (2003).

31. Wu, X., Xu, L. Y., Li, E. M. & Dong, G. Application of molecular dynamics simulation in biomedicine. *Chem. Biol. Drug Des.* **99**, 789–800 (2022).

32. Wang, R. S. S-System. In *Encyclopedia of systems biology*. Dubitzky, W. et al. (Eds), https://doi.org/10.1007/978-1-4419-9863-7_386 (Springer, New York, NY, 2013).

33. Bressloff, P. C. & Newby, J. M. Stochastic models of intracellular transport. *Rev. Mod. Phys.* **85**, 135–196 (2013).

34. González, P. P. et al. Cellulat: an agent-based intracellular signalling model. *Biosystems* **68**, 171–185 (2003).

35. Tang, Y. & Hoffmann, A. Quantifying information of intracellular signaling: progress with machine learning. *Rep. Prog. Phys.* **85**, 086602 (2022).

36. Ao, Y. et al. Lamin A buffers CK2 kinase activity to modulate aging in a progeria mouse model. *Sci. Adv.* **5**, eaav5078 (2019).
-
37. Senebandith, H. et al. Multi-site phosphorylation of the TOPBP1 ATR activation domain propels ATR signaling during the response to DNA breaks. Preprint at *bioRxiv* <https://doi.org/10.1101/2022.09.19.508511> (2022).
-
38. Roessler, H. I., Knoers, N., van Haelst, M. M. & van Haaften, G. Drug repurposing for rare diseases. *Trends Pharm. Sci.* **42**, 255–267 (2021).
-
39. Jayanth, N. et al. Drug repurposing screen for the rare disease ataxia-telangiectasia. *SLAS Discov.* **30**, 100200 (2025).
-
40. Phan, L. M. & Rezaeian, A. H. ATM: main features, signaling pathways, and its diverse roles in DNA damage response, tumor suppression, and cancer development. *Genes* **12**, 845 (2021).
-
41. Weber, A. M. & Ryan, A. J. ATM and ATR as therapeutic targets in cancer. *Pharm. Ther.* **149**, 124–138 (2015).
-
42. Jazayeri, A. et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. *Nat. Cell Biol.* **8**, 37–45 (2006).
-

43. Cheng, A. et al. ATM and ATR play complementary roles in the behavior of excitatory and inhibitory vesicle populations. *Proc. Natl Acad. Sci. USA* **115**, E292–E301 (2018).
44. Chang, K. C. et al. The interplay of autophagy and oxidative stress in the pathogenesis and therapy of retinal degenerative diseases. *Cell Biosci.* **12**, 1 (2022).
45. Herrup, K. ATM and the epigenetics of the neuronal genome. *Mech. Ageing Dev.* **134**, 434–439 (2013).
46. Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. *Nucl. Acids Res.* **28**, 27–30 (2000).
47. R. Core Team. R: a language and environment for statistical computing. *R Foundation for Statistical Computing* (2024).
48. Yu, G. & He, Q. Y. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. *Mol. Biosyst.* **12**, 477–479 (2016).
49. Szklarczyk, D. et al. "The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res.* **51**, D638–D646 (2023).

50. Khatri, P., Sirota, M. & Butte, A. J. Ten years of pathway analysis: current approaches and outstanding challenges. *PLoS Comput. Biol.* **8**, e1002375 (2012).
51. Mendes, P. GEPASI: a software package for modelling the dynamics, steady states and control of biochemical and other systems. *Comput. Appl. Biosci.* **9**, 563–571 (1993).
52. Hu, A. et al. Modeling of DNA damage repair and cell response in relation to p53 system exposed to ionizing radiation. *Int. J. Mol. Sci.* **23**, 11323 (2022).
53. Guo, X. et al. Computational drug repurposing in Parkinson's disease: omaveloxolone and cyproheptadine as promising therapeutic candidates. *Front. Pharm.* **16**, 1539032 (2025).
54. Wang, H. et al. Spermidine promotes Nb CAR-T mediated cytotoxicity to lymphoma cells through elevating proliferation and memory. *Onco. Target Ther.* **15**, 1229–1243 (2022).
55. Kim, D. H. et al. Spermidine attenuates oxidative stress-induced apoptosis via blocking Ca²⁺ overload in retinal pigment epithelial cells independently of ROS. *Int. J. Mol. Sci.* **22**, 1361 (2021).
56. Saltelli, A. et al. *Global Sensitivity Analysis: The Primer* (Wiley, 2008).

57. Marino, S., Hogue, I. B., Ray, C. J. & Kirschner, D. E. A methodology for performing global uncertainty and sensitivity analysis in systems biology. *J. Theor. Biol.* **254**, 178–196 (2008).
58. Wolf, A., Swift, J. B., Swinney, H. L. & Vastano, J. A. Determining Lyapunov exponents from a time series. *Phys. D: Nonlinear Phenom.* **16**, 285–317 (1985).

Acknowledgements

This work was supported in part by the Italian Ministry of Health, Piano di Sviluppo e Coesione del Ministero della Salute 2014–2020, Project: Pharma-HUB—Hub per il riposizionamento di farmaci nelle malattie rare del sistema nervoso in età pediatrica (CUP E63C22001680001 - ID T4-AN-04).

Author information

These authors contributed equally: Aurora Eliana Merulla, Valentina Di Salvatore, Giorgia Serena Gullotta.

Authors and Affiliations

Department of Physics and Astronomy, University of Catania, Catania, Italy

Aurora Eliana Merulla

Department of Drug and Health Sciences, University of Catania, Catania, Italy

Valentina Di Salvatore, Avisa Maleki, Giulia Russo, Filippo Caraci, Agata Copani & Francesco Pappalardo

Oasi Research Institute-IRCCS, Unit of Neuropharmacology and Translational Neurosciences, Troina, Italy

Giorgia Serena Gullotta & Filippo Caraci

Oasi Research Institute-IRCCS, Unit of Bioinformatics and Statistics, Troina, Italy

Giulia Russo

Contributions

A.E.M. and G.S.G. performed the experiments, carried out the formal analyses, and wrote the draft of the manuscript. V.D.S. performed the experiments and statistical analysis and contributed to both the original draft and its revision. A.M. conducted formal analysis and contributed to writing the original draft. G.R. curated the data and contributed to writing and revising the manuscript. F.C. and A.C. revised the manuscript and provided critical input. F.P. conceived the study, developed the main conceptual framework, and supervised the methodology. All authors have read and approved the final version of the manuscript.

Corresponding author

Correspondence to [Francesco Pappalardo](#).

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

[Supplementary Information](#)

[Transparent Peer Review file](#)

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

<http://creativecommons.org/licenses/by-nc-nd/4.0/>.

[Reprints and permissions](#)

About this article

Cite this article

Merulla, A.E., Di Salvatore, V., Gullotta, G.S. *et al.* Computational modeling of ATM signaling: a predictive framework for drug repurposing in ataxia-telangiectasia. *npj Syst Biol Appl* (2025). <https://doi.org/10.1038/s41540-025-00629-4>

Received

28 March 2025

Accepted

14 November 2025

Published

24 November 2025

DOI

<https://doi.org/10.1038/s41540-025-00629-4>

Share this article

Anyone you share the following link with will be able to read this content:

[Get shareable link](#)

Provided by the Springer Nature SharedIt content-sharing initiative

Subjects

[Biochemical networks equations](#) • [Diseases](#) • [Computational biology and bioinformatics](#) • [Software](#) • [Differential](#)

npj Systems Biology and Applications (*npj Syst Biol Appl*) | ISSN 2056-7189 (online)